Literature DB >> 8629860

Tumor necrosis factor alpha gene expression in human monocytic THP-1 cells exposed to beryllium.

G M Galbraith1, J P Pandey, M G Schmidt, P Arnaud, J M Goust.   

Abstract

Chronic beryllium disease, which results from occupational exposure to particulate beryllium, is characterized by the development of lung granulomas and progressive pulmonary fibrosis. Increased production of proinflammatory cytokines (e.g., tumor necrosis factor alpha and interleukin-1 beta) by pulmonary alveolar macrophages occurs in many chronic fibrotic lung diseases and is thought to contribute to the disease process. The purpose of the present study was to investigate cytokine production by human monocytic cells exposed to beryllium in vitro. The results indicated that such cells respond to beryllium ions in the presence of fluoride by accumulation of messenger ribonucleic acid for both tumor necrosis factor alpha and interleukin-1 beta. These findings suggest that inhaled beryllium may directly stimulate the production of these cytokines by alveolar macrophages in vitro.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8629860     DOI: 10.1080/00039896.1996.9935990

Source DB:  PubMed          Journal:  Arch Environ Health        ISSN: 0003-9896


  4 in total

1.  Beryllium, an adjuvant that promotes gamma interferon production.

Authors:  J Y Lee; O Atochina; B King; L Taylor; M Elloso; P Scott; M D Rossman
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 2.  Immunologic Effects of Beryllium Exposure.

Authors:  Andrew P Fontenot
Journal:  Ann Am Thorac Soc       Date:  2018-04

Review 3.  Beryllium-Induced Hypersensitivity: Genetic Susceptibility and Neoantigen Generation.

Authors:  Andrew P Fontenot; Michael T Falta; John W Kappler; Shaodong Dai; Amy S McKee
Journal:  J Immunol       Date:  2016-01-01       Impact factor: 5.422

Review 4.  Interstitial fibrosis and growth factors.

Authors:  J A Lasky; A R Brody
Journal:  Environ Health Perspect       Date:  2000-08       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.